{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "esgPopulated": false, "market": "us_market", "longName": "Viking Therapeutics, Inc.", "marketState": "PRE", "regularMarketPrice": 22.53, "messageBoardId": "finmb_246791410", "exchange": "NCM", "shortName": "Viking Therapeutics, Inc.", "exchangeTimezoneShortName": "EDT", "exchangeTimezoneName": "America/New_York", "regularMarketChangePercent": -1.6586608, "gmtOffSetMilliseconds": -14400000, "fiftyTwoWeekLowChange": 20.51, "fiftyTwoWeekLowChangePercent": 10.153465, "fiftyTwoWeekRange": "2.02 - 23.5", "fiftyTwoWeekHighChange": -0.9699993, "fiftyTwoWeekHighChangePercent": -0.041276567, "fiftyTwoWeekLow": 2.02, "fiftyTwoWeekHigh": 23.5, "earningsTimestamp": 1682541000, "earningsTimestampStart": 1690315200, "earningsTimestampEnd": 1690833600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.92, "epsForward": -0.94, "epsCurrentYear": -0.83, "firstTradeDateMilliseconds": 1430227800000, "priceHint": 2, "preMarketChange": -0.11000061, "preMarketChangePercent": -0.4882406, "preMarketTime": 1684155252, "preMarketPrice": 22.42, "regularMarketChange": -0.37999916, "regularMarketTime": 1683921604, "regularMarketDayHigh": 23.245, "regularMarketDayRange": "22.0201 - 23.245", "regularMarketDayLow": 22.0201, "regularMarketVolume": 1608923, "regularMarketPreviousClose": 22.91, "bid": 20.03, "ask": 22.49, "bidSize": 10, "askSize": 8, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 23.13, "averageDailyVolume3Month": 4655363, "averageDailyVolume10Day": 2509830, "priceEpsCurrentYear": -27.144579, "sharesOutstanding": 99839400, "bookValue": 1.69, "fiftyDayAverage": 16.6014, "fiftyDayAverageChange": 5.9286003, "fiftyDayAverageChangePercent": 0.35711446, "twoHundredDayAverage": 8.2739, "twoHundredDayAverageChange": 14.256101, "twoHundredDayAverageChangePercent": 1.7230207, "marketCap": 2265346560, "forwardPE": -23.968086, "priceToBook": 13.331361, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Viking Therapeutics", "symbol": "VKTX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 56, "title": "Pres, CEO & Director", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 965115, "fmt": "965.12k", "longFmt": "965,115"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5242550, "fmt": "5.24M", "longFmt": "5,242,550"}}, {"maxAge": 1, "name": "Mr. Gregory S. Zante", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 603500, "fmt": "603.5k", "longFmt": "603,500"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 366013, "fmt": "366.01k", "longFmt": "366,013"}}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 57, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 633300, "fmt": "633.3k", "longFmt": "633,300"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1412689, "fmt": "1.41M", "longFmt": "1,412,689"}}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 57, "title": "VP of Fin. & Admin.", "yearBorn": 1965, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Sr. VP of Pharmaceutical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}